Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1527

Sort by

Sort Order Select

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Martin F. Kaiser, Matthew Jenner, MBBS, MRCP, FRCPath, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Andrea Paterson, Rebecca Mottram, BA, BSc, Faith E. Davies, MD, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Gareth Morgan, MDPhDFRCP, Gordon Cook, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD

Blood (2019) 134 (Supplement_1): 604.

https://doi.org/10.1182/blood-2019-124819

Published: 2019

Journal Articles

Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

Gayathri Ravi, MD, Kamal Chamoun, MD, Kirsten M Boughan, DO, Shufen Cao, Pingfu Fu, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 424.

https://doi.org/10.1182/blood-2019-126131

Published: 2019

Journal Articles

N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia

Ya Zhang, MD, Xiaosheng Fang, PhD, Na Chen, MD, Xiao Lv, PhD, Xueling Ge, PhD, Kang Lu, MD PhD, Xiangxiang Zhou, MD, Juan Yang, MM, Yang Han, MM, Shunfeng Hu, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 1738.

https://doi.org/10.1182/blood-2019-126469

Published: 2019

Journal Articles

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1861.

https://doi.org/10.1182/blood-2019-130845

Published: 2019

Journal Articles

Risk of Progression in Patients with Smoldering Myeloma

Fahrettin Covut, MD, Kamal Chamoun, MD, Leland Metheny, III, MD, Kirsten M Boughan, DO, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 1892.

https://doi.org/10.1182/blood-2019-127677

Published: 2019

Journal Articles

Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI

Laura Korin, MD, Maria Del Rosario Custidiano, MD, Maria Lucia Fuente, Santiago Cranco, MD, Adriana Vitriu, MD, Paola Ochoa, MD, Evelina Babuin, Fernando Diaz Couselo, MD, Anahí Vijnovich Baron, MD, Paula Tempra, Maria Belen Venegas, Andrea Novoa, Norma Elisabeth Tartas, MD, Maria Cecilia Foncuberta, MD, Julio Cesar Sanchez Avalos, MD

Blood (2019) 134 (Supplement_1): 1625.

https://doi.org/10.1182/blood-2019-126193

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma

Lijuan Chen, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 1808.

https://doi.org/10.1182/blood-2019-123982

Published: 2019

Journal Articles

Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Marie Lindgren, Erik Ahlstrand, MD PhD, Helna Pettersson, MD, Maria Liljeholm, Anna Ravn-Landtblom, MD, Stefan Scheding, Prof, Björn Andréasson, MD PhD, Jan Samuelsson, MD PhD

Blood (2019) 134 (Supplement_1): 1658.

https://doi.org/10.1182/blood-2019-124374

Published: 2019

Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1751.

https://doi.org/10.1182/blood-2019-127102

Published: 2019

Journal Articles

Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients

Nicola Polverelli, Paolo Tura, Giorgia Battipaglia, MD, Gandolfi Lisa, Tatiana Zollner, MD, Michele Malagola, MD, Enrico Morello, MD, Alessandro Turra, MD, Simona Bernardi, PhD, Camilla Zanaglio, PhD, Federica Re, Mohamad Mohty, MD PhD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 41.

https://doi.org/10.1182/blood-2019-127026

Published: 2019

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 45.

https://doi.org/10.1182/blood-2019-124765

Published: 2019

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

https://doi.org/10.1182/blood-2019-125155

Published: 2019

Journal Articles

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem Solh, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 2006.

https://doi.org/10.1182/blood-2019-123230

Published: 2019

Journal Articles

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Masakatsu Hishizawa, MD PhD, Masahito Tokunaga, MD PhD, Atsushi Wake, MD PhD, Nobuaki Nakano, MD, Tetsuya Eto, MD PhD, Michihiro Hidaka, MD PhD, Ilseung Choi, MD PhD, Toshihiro Miyamoto, MD PhD, Naoyuki Uchida, MD PhD, Yukiyoshi Moriuchi, MD, Yasuhiko Miyazaki, MD PhD, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, MD PhD, Koji Kato, MD PhD

Blood (2019) 134 (Supplement_1): 2008.

https://doi.org/10.1182/blood-2019-123318

Published: 2019

Journal Articles

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34 + progenitor Cells

Alexandra Gomez-Arteaga, MD, Nina Orfali, MB,PhD, Danielle Guarneri, BS, CCRP, Usama Gergis, MD MBA, Sebastian A. Mayer, MD, Jingmei Hsu, MD, Adrienne A. Phillips, MD MPH, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD

Blood (2019) 134 (Supplement_1): 2040.

https://doi.org/10.1182/blood-2019-129584

Published: 2019

NARROW

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches

Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients

N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Risk of Progression in Patients with Smoldering Myeloma

Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma

Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34 + progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only